Featuring an interview with Dr Eunice S Wang, including the following topics:

• Hypomethylating agent/venetoclax combinations for the treatment of acute myeloid leukemia (AML); integration in community practice (0:00)
• All-oral regimen of decitabine/cedazuridine with venetoclax for patients with newly diagnosed AML not eligible for intensive induction chemotherapy (9:39)
• Efficacy of targeted therapy options for AML; potential role of MRD (minimal residual disease) assays in monitoring treatment response (13:07)
• Treatment approach for patients with FLT3-mutant AML; mutation profiles and predicting response to quizartinib (20:14)
• Targeting the differentiation of AML tumor cells with IDH and menin inhibitors; associated differentiation syndrome (29:24)
• Efficacy and tolerability of the IDH inhibitors ivosidenib and olutasidenib (36:54)
• Key clinical data with approved and investigational menin inhibitors for AML; current and potential integration of menin inhibitors in the AML treatment algorithm (42:30)

CME information and select publications